Mostrar el registro sencillo del ítem

dc.contributor.authorRamos, Mónica
dc.contributor.authorQuezada-Feijoó, Maribel
dc.contributor.authorAyala, Rocío
dc.contributor.authorManzano, Ascención
dc.contributor.authorGómez-Pavón, Francisco Javier
dc.contributor.authorJaramillo, Javier
dc.contributor.authorHerrera, Cristina
dc.contributor.authorLópez Vazquez de la Torre, Mariola
dc.contributor.authorToro Cebada, Rocío 
dc.contributor.otherCirugíaes_ES
dc.contributor.otherMedicina
dc.date.accessioned2024-04-24T11:26:16Z
dc.date.available2024-04-24T11:26:16Z
dc.date.issued2023
dc.identifier.issn2077-0383
dc.identifier.urihttp://hdl.handle.net/10498/31955
dc.description.abstractRecognizing symptoms in elderly patients with severe aortic stenosis (AS) can be a challenge. Serum biomarkers such as Galectin-3 or N-terminal prohormone B-type natriuretic peptide (NT-proBNP) are involved in remodeling and heart failure (HF) development and could support the diagnosis of AS. We set out to test the usefulness of NT-proBNP and Galectin-3 in predicting events in this population. We designed a prospective observational case–control study, including 50 asymptomatic patients older than 70 years, diagnosed with severe degenerative AS, and 50 control individuals. The NT-proBNP and Galectin-3 levels were measured. A follow-up was carried out at 12 months to determine the occurrence of hospital admission for HF, all-cause mortality or the appearance of symptoms. The patients with severe AS had higher Galectin-3 and NT-proBNP concentrations. The area under the receiver operating characteristic curve of the NT-proBNP was 0.812 (95% CI, 0.646–0.832), and that of the Galectin-3 was 0.633 (95% CI, 0.711–0.913). NT-proBNP was a good predictor of events [HR 3.45 (95% CI 1.32–9.03), p = 0.011]. A Kaplan–Meier analysis showed that the probability of freedom from events was significant in patients who exhibited a combination of higher NT-proBNP and Galectin-3 levels (log-rank p = 0.032). Therefore, NT-proBNP was the most reliable predictor of events in asymptomatic patients with severe AS. A combination of NT-proBNP and Galectin-3 levels may be vital in the clinical follow-up of these patients and in the decision-making process.es_ES
dc.formatapplication/pdfes_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceJournal of Clinical Medicine - 2023, Vol. 12 n. 8 pp. 1-15es_ES
dc.subjectaortic stenosises_ES
dc.subjectolder patientses_ES
dc.subjectcongestive heart failurees_ES
dc.subjectGalectin-3es_ES
dc.subjectNT-proBNPes_ES
dc.titleValue of NT-proBNP and Galectin-3 as Biomarkers in the Follow-Up of Asymptomatic Elderly Patients with Severe Aortic Stenosises_ES
dc.typejournal articlees_ES
dc.rights.accessRightsopen accesses_ES
dc.identifier.doi10.3390/JCM12082987
dc.relation.projectIDPI0012_2019es_ES
dc.relation.projectID1,011,006es_ES
dc.relation.projectIDITI PI0017-2019es_ES
dc.type.hasVersionVoRes_ES


Ficheros en el ítem

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
Esta obra está bajo una Licencia Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 Internacional